An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
Pulmonary arterial hypertension (PAH) is a serious condition caused by high blood pressure in the blood vessels that supply the lungs. It can make everyday activities difficult due to breathlessness and tiredness. This phase 3 clinical trial is investigating a medicine called sotatercept. Participants take sotatercept as an add-on treatment alongside their standard PAH medicines. The trial is 'open-label', meaning both you and your study doctors will know you are receiving the real study medicine rather than a dummy treatment (placebo). Researchers are tracking the long-term safety of sotatercept by checking for side effects, monitoring blood tests, and performing heart scans. They also want to find out if the treatment helps people walk further in six minutes and improves their overall quality of life. The study welcomes men and women aged 18 and older who have PAH.
At a glance
What is this study about?
Pulmonary arterial hypertension, often shortened to PAH, is a rare and serious health condition. In people with PAH, the blood vessels that carry blood from the heart to the lungs become stiff, narrowed, or blocked. This makes it much harder for the heart to pump blood through the lungs, leading to high blood pressure in those vessels. Over time, this puts extra strain on the heart muscle and can cause breathlessness, dizziness, chest discomfort, and severe fatigue.
While there are existing medications that help open up these blood vessels, researchers are searching for new treatments that can work in different ways to improve quality of life and protect the heart. This study focuses on an investigational medicine called sotatercept. Instead of just relaxing the blood vessels, sotatercept is designed to rebalance certain cellular signals that may be driving the thickening of vessel walls in the lungs.
This specific trial is a long-term follow-up study. Its main purpose is to find out what happens when people take sotatercept over an extended period alongside their normal PAH medications. Doctors will closely track how safe the drug is, watch for any unwanted side effects, and check whether it continues to help patients feel better and stay active. Taking part helps researchers understand if sotatercept could become a valuable long-term option for people living with PAH.
Key takeaways
- Testing a new medicine called sotatercept for pulmonary arterial hypertension (PAH).
- Open to adults aged 18 and older who are already receiving treatment for PAH.
- This is an open-label study, meaning every participant receives the active drug.
- The main aim is to evaluate the long-term safety and overall health benefits of the medicine.
- Involves regular hospital check-ups, walking tests, blood tests, and heart monitoring.
Who may be eligible?
This study is open to adults aged 18 and over who have been diagnosed with pulmonary arterial hypertension (PAH). Both men and women can join. Because this is an extension study, many participants will be people who have already taken part in an earlier sotatercept clinical trial.
To be suitable, you must already be receiving standard medical treatment for your PAH. Your general health must also allow you to attend regular hospital appointments and undergo routine health checks, such as blood tests and heart monitoring.
You may not be able to join if you have certain other severe medical conditions that could make taking part unsafe, or if you cannot commit to the required clinic visits. The trial doctor will review your full medical history and current prescriptions to make sure joining the trial is appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or over.
- I have been diagnosed with pulmonary arterial hypertension (PAH).
- I am currently taking standard prescribed treatment for my PAH.
- I am willing to attend regular hospital appointments for check-ups and tests.
- I am open to receiving an injection under the skin as part of my treatment plan.
What does participation involve?
If you take part, you will receive sotatercept in addition to your regular PAH prescription medicines. Because this is an open-label study, there is no dummy drug (placebo); everyone in the trial receives the active medicine. The treatment is given as an injection under the skin at scheduled intervals.
You will need to visit the hospital clinic regularly throughout the study. During these visits, the medical team will run safety checks including blood and urine tests, blood pressure checks, and heart traces (electrocardiograms, or ECGs). They will also measure how far you can walk in six minutes to see if your exercise capacity is improving. You may also have specialised heart tests to see how easily blood is moving through your lungs. The study involves long-term follow-up, which may last for several months or years, and the study team will outline the exact visit schedule with you before you agree to join.
Potential risks and benefits
Locations (14)
- —UnverifiedPoland
- —UnverifiedBelgium
- —UnverifiedSweden
- —UnverifiedFrance
- —UnverifiedPortugal
- —UnverifiedNetherlands
- —UnverifiedCroatia
- —UnverifiedDenmark
- —UnverifiedItaly
- —UnverifiedGermany
- —UnverifiedCzechia
- —UnverifiedGreece
Common questions
What does 'open-label' mean?
Open-label means that both you and your medical team know exactly which medicine you are receiving. There is no placebo (dummy medicine) used in this study.
Will I have to stop my current PAH medicines?
No. Sotatercept is designed to be taken as an 'add-on' treatment alongside your existing, prescribed PAH medications.
How is the study medicine given?
Sotatercept is given as an injection just under the skin (subcutaneously), similar to how insulin or some other regular treatments are given.
Does taking part cost anything?
No. The study medication and all trial-related tests are provided free of charge, and travel expenses to hospital visits are typically reimbursed.
Can I leave the study if I change my mind?
Yes. Joining is completely voluntary. You can leave the study at any time, for any reason, without your standard medical care being affected.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.